Citations (33)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Jinyi Lang, Chaosu Hu, Taixiang Lu, Jianji Pan & Tongyu Lin. (2019) Chinese expert consensus on diagnosis and treatment of nasopharyngeal carcinoma: evidence from current practice and future perspectives. Cancer Management and Research 11, pages 6365-6376.
Read now
Read now
Stefan Hartmann & Jennifer R. Grandis. (2016) Treatment of head and neck cancer in the elderly. Expert Opinion on Pharmacotherapy 17:14, pages 1903-1921.
Read now
Read now
Pol M Specenier & Jan B Vermorken. (2008) Recurrent head and neck cancer: current treatment and future prospects. Expert Review of Anticancer Therapy 8:3, pages 375-391.
Read now
Read now
Articles from other publishers (30)
Zachariah Thomas, Prashant Jambunathan, Anjali Jibi, Ajoy Oommen John & Ashish Singh. (2023) Low-dose nivolumab and cabozantinib in recurrent intestinal-type papillary adenocarcinoma of the sinonasal region. BMJ Case Reports 16:11, pages e255021.
Crossref
Crossref
Shuhang Wang, Peiwen Ma, Ning Jiang, Yale Jiang, Yue Yu, Yuan Fang, Huilei Miao, Huiyao Huang, Qiyu Tang, Dandan Cui, Hong Fang, Huishan Zhang, Qi Fan, Yuning Wang, Gang Liu, Zicheng Yu, Qi Lei & Ning Li. (2023) Rare tumors: a blue ocean of investigation. Frontiers of Medicine 17:2, pages 220-230.
Crossref
Crossref
M V Chandrakanth, Vivek Agarwala, Pradip Mondal, Raajit Chanana, K M Parthasarathy, Sourav Dutta, Harsh Dhar, Suman Mallick, Sayan Das, Devmalya Banerjee, Md Arif Faizan, Moinak Basu & Subhabrata Kumar. (2023) Weekly paclitaxel, carboplatin and cetuximab (PCC) combination followed by nivolumab in platinum-sensitive recurrent and /or metastatic squamous cell carcinoma of head and neck: a retrospective analysis from two institutions in India. F1000Research 12, pages 802.
Crossref
Crossref
Rebecca Forman, Hari Deshpande, Barbara Burtness & Aarti K. Bhatia. (2022) Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer with a focus on elderly or frail patients. Head & Neck 44:8, pages 1777-1786.
Crossref
Crossref
Muhammad Shahid Iqbal, Josef Kovarik, Rahul Patil & Charles G. Kelly. (2022) Are taxanes more effective than 5FU in combination chemotherapy for recurrent and metastatic head and neck cancer?. Oral Oncology 124, pages 105455.
Crossref
Crossref
Huanhuan Wang, Qin Zhao, Yangyu Zhang, Jinlong Wei, Bin Wang, Zhuangzhuang Zheng, Shiyu Liu, Zijing Liu, Lingbin Meng, Ying Xin & Xin Jiang. (2021) Efficacy and safety of systemic treatments for patients with recurrent/metastatic head and neck squamous cell carcinoma: A systematic review and network meta-analysis. Pharmacological Research 173, pages 105866.
Crossref
Crossref
David G. PfisterSharon SpencerDavid AdelsteinDouglas AdkinsYoshimi AnzaiDavid M. BrizelJustine Y. BrucePaul M. BusseJimmy J. CaudellAnthony J. CmelakA. Dimitrios ColevasDavid W. EiseleMoon FentonRobert L. FooteThomas GallowayMaura L. GillisonRobert I. HaddadWesley L. HicksYing J. HitchcockAntonio JimenoDebra LeizmanEllie MaghamiLoren K. MellBharat B. MittalHarlan A. PintoJohn A. RidgeJames W. RoccoCristina P. RodriguezJatin P. ShahRandal S. WeberGregory WeinsteinMatthew WitekFrank WordenSue S. YomWeining Zhen, Jennifer L. Burns & Susan D. Darlow. (2020) Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network 18:7, pages 873-898.
Crossref
Crossref
Alison G. Chang & Deborah J. Wong. 2020. Novel Therapies in Head and Neck Cancer: Beyond the Horizon. Novel Therapies in Head and Neck Cancer: Beyond the Horizon
17
38
.
Gil Harmon & Justine Yang Bruce. 2020. Improving the Therapeutic Ratio in Head and Neck Cancer. Improving the Therapeutic Ratio in Head and Neck Cancer
33
47
.
Constantine Alifrangis, Ursula McGovern, Alex Freeman, Thomas Powles & Mark Linch. (2019) Molecular and histopathology directed therapy for advanced bladder cancer. Nature Reviews Urology 16:8, pages 465-483.
Crossref
Crossref
Jean-Nicolas Gallant, Andrew Sewell, Karinna Almodovar, Qingguo Wang, Kimberly B. Dahlman, Richard G. Abramson, Meghan E. Kapp, Brandee T. Brown, Kelli L. Boyd, Jill Gilbert, Daniel N. Cohen, Wendell G. Yarbrough, Zhongming Zhao & Christine M. Lovly. (2019) Genomic landscape of a metastatic malignant proliferating tricholemmal tumor and its response to PI3K inhibition. npj Precision Oncology 3:1.
Crossref
Crossref
Renata Ferrarotto, William N. WilliamJr.Jr., Jennifer E. Tseng, Shanthi Marur, Dong M. Shin, Barbara Murphy, Ezra E.W. Cohen, Christopher Y. Thomas, Richard Willey, Jan Cosaert, Nusrat Harun, J. Jack Lee, Ignacio W. Wistuba, Robert I. Haddad & Bonnie S. Glisson. (2018) Randomized phase II trial of cixutumumab alone or with cetuximab for refractory recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology 82, pages 83-90.
Crossref
Crossref
Marie Shimanuki, Yorihisa Imanishi, Yoichiro Sato, Nana Nakahara, Daisuke Totsuka, Emiri Sato, Sena Iguchi, Yasuo Sato, Keiko Soma, Yasutomo Araki, Seiji Shigetomi, Satoko Yoshida, Kosuke Uno, Yusuke Ogawa, Takehiro Tominaga, Yuichi Ikari, Junko Nagayama, Ayako Endo, Koshiro Miura, Takuya Tomioka, Hiroyuki Ozawa & Kaoru Ogawa. (2018) Pretreatment monocyte counts and neutrophil counts predict the risk for febrile neutropenia in patients undergoing TPF chemotherapy for head and neck squamous cell carcinoma. Oncotarget 9:27, pages 18970-18984.
Crossref
Crossref
Cory D. Fulcher, Missak HaigentzJrJr & Thomas J. Ow. (2018) AHNS Series: Do you know your guidelines? Principles of treatment for locally advanced or unresectable head and neck squamous cell carcinoma. Head & Neck 40:4, pages 676-686.
Crossref
Crossref
Susumu Nakahara, Atsushi Hanamoto, Yuji Seo, Shinichi Miyaguchi, Yoshifumi Yamamoto, Yoichiro Tomiyama, Tadashi Yoshii, Yukinori Takenaka, Yasuo Yoshioka, Fumiaki Isohashi, Kazuhiko Ogawa & Hidenori Inohara. (2016) Chemoradiotherapy with weekly low-dose docetaxel and cisplatin concurrent with radiation for patients with locally advanced nasopharyngeal carcinoma, followed by adjuvant chemotherapy for selected patients†. Japanese Journal of Clinical Oncology 46:10, pages 903-910.
Crossref
Crossref
Petr Szturz & Jan B. Vermorken. 2016. Head and Neck Cancer. Head and Neck Cancer
711
729
.
Cecilia Arana Yi, Peter McCue, Marc Rosen, Mitchell Machtay, Rita Axelrod & Gloria J. Morris. (2013) Sarcoidosis Mimicking Metastatic Bone Disease in Head and Neck Cancer. Seminars in Oncology 40:5, pages 529-534.
Crossref
Crossref
Yukinori Takenaka, Hironori Cho, Masashi Yamamoto, Susumu Nakahara, Yoshifumi Yamamoto & Hidenori Inohara. (2013) Incidence and predictors of febrile neutropenia during chemotherapy in patients with head and neck cancer. Supportive Care in Cancer 21:10, pages 2861-2868.
Crossref
Crossref
Anne Tsao, Edwin Pun Hui, Rosalyn Juergens, Shanthi Marur, Tan Eng Huat, Goh Boon Cher, Ruey‐Long Hong, Waun Ki Hong & Anthony Tak‐Cheung Chan. (2013)
Phase II study of
TAS
‐106 in patients with platinum‐failure recurrent or metastatic head and neck cancer and nasopharyngeal cancer
. Cancer Medicine 2:3, pages 351-359.
Crossref
Crossref
Albert Tiong & June Corry. 2013. Radiation Oncology in Palliative Cancer Care. Radiation Oncology in Palliative Cancer Care
126
144
.
Missak HaigentzJr.Jr., Mimi Kim, Catherine Sarta, Juan Lin, Roger S. Keresztes, Bruce Culliney, Anu G. Gaba, Richard V. Smith, Geoffrey I. Shapiro, Lucian R. Chirieac, John M. Mariadason, Thomas J. Belbin, John M. Greally, John J. Wright & Robert I. Haddad. (2012) Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer. Oral Oncology 48:12, pages 1281-1288.
Crossref
Crossref
Peter Mu-Hsin Chang, Cheng-Hwai Tzeng, Ming-Huang Chen, Chao-Jung Tsao, Wu-Chou Su, Wei-Shuo Hwang, Yi-Fang Chang, Shyue-Yih Chang & Muh-Hwa Yang. (2011) Triweekly reduced-dose docetaxel combined with cisplatin in recurrent/metastatic head and neck squamous cell carcinoma: a multicenter phase II study. Cancer Chemotherapy and Pharmacology 68:6, pages 1477-1484.
Crossref
Crossref
Susanne M. Arnold, James Moon, Stephen K. Williamson, James N. Atkins, Sai-Hong I. Ou, Michael LeBlanc & Susan G. Urba. (2009) Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618. Investigational New Drugs 29:2, pages 352-359.
Crossref
Crossref
Imjai Chitapanarux, Vicharn Lorvidhaya, Ekasit Tharavichitkul, Somvilai Mayurasakorn, Pichit Sittitrai, Tienchai Pattarasakulchai, Rak Tananuwat & Chonticha Srivanitchapoom. (2011) A phase II study of docetaxel and carboplatin with concurrent radiation therapy for locally advanced head and neck cancer. Auris Nasus Larynx 38:1, pages 108-113.
Crossref
Crossref
Jan B. Vermorken. 2011. Head and Neck Cancer. Head and Neck Cancer
651
664
.
J.B. Vermorken & P. Specenier. (2010) Optimal treatment for recurrent/metastatic head and neck cancer. Annals of Oncology 21, pages vii252-vii261.
Crossref
Crossref
Stephen K. WilliamsonJames MoonChao H. HuangPerry P. GuaglianoneMichael LeBlancGregory T. WolfSusan G. Urba. (2010) Phase II Evaluation of Sorafenib in Advanced and Metastatic Squamous Cell Carcinoma of the Head and Neck: Southwest Oncology Group Study S0420. Journal of Clinical Oncology 28:20, pages 3330-3335.
Crossref
Crossref
Anne S. Tsao. (2009) Novel therapies in metastatic head and neck squamous cell carcinoma. Community Oncology 6:7, pages 310-316.
Crossref
Crossref
Pol M. Specenier & Jan B. Vermorken. (2009) Current concepts for the management of head and neck cancer: Chemotherapy. Oral Oncology 45:4-5, pages 409-415.
Crossref
Crossref
. (2008) Current World Literature. Current Opinion in Otolaryngology & Head & Neck Surgery 16:2, pages 175-182.
Crossref
Crossref